Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | MMP2 | P08253 | 4/20 | 0.40 |
| ▸ | ANPEP | P15144 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7348775 | 1.00 | ATM (0.63) | ATMMMP2ANPEPPOLBACE | |
| SCHEMBL25364067 | 0.83 | ATM (0.42) | ATMACE | |
| SCHEMBL992740 | 0.78 | — | — | |
| SCHEMBL17541277 | 0.78 | — | — | |
| Oxaceprol SCHEMBL3780150 | 0.78 | ATM (1.00) | ATMMMP2ANPEPACE | |
| SCHEMBL19083914 | 0.78 | ATM (0.66) | ATMMMP2ANPEPPOLB | |
| Oxaceprol SCHEMBL25977 | 0.78 | ATM (1.00) | ATMMMP2ANPEPACE | |
| SCHEMBL16748604 | 0.78 | ATM (0.71) | ATMMMP2ANPEPPOLB | |
| Oxaceprol SCHEMBL1285600 | 0.78 | ATM (1.00) | ATMMMP2ANPEPACE | |
| Oxaceprol SCHEMBL25978 | 0.78 | ATM (1.00) | ATMMMP2ANPEPACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3166939-B1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20120022040-A1 | ANTIMICROBIALS | AMPLYX PHARMACEUTICALS, INC. | 2012-01-26 | — | — | US | disclosed |
| US-4316906-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022040-A1 | ANTIMICROBIALS | PAM, MPO, OXA1L | ATM 3232/4885MMP2 828/4885ANPEP 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.